Background Up to half of patients with infective endocarditis (IE) require cardiac surgery. Although anaemia is common, its precise prevalence, transfusion practices and impact on outcomes in ...
The leading cause of death due to injuries in war is excessive bleeding. A KAIST research team, in which an Army Major ...
Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.
TipRanks on MSN
Innovent wins landmark China approval for first domestic CTLA-4 neoadjuvant colon cancer therapy
Innovent Biologics ( ($HK:1801) ) has provided an update. Innovent Biologics announced that China’s National Medical Products Administration has ...
Abstract: Control of haptic systems with complex and unstructured environments like the endonasal sinus region, which is used in surgical simulators, puts fundamental challenges forward. This study ...
China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...
This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...
PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in patients with inflammatory bowel disease who have ulcerative colitis. The lack ...
In a major policy reversal, the Trump administration has ordered the CDC to cease all scientific research involving primates, ...
New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.
Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback